PA
CTMX icon

Perceptive Advisors’s CytomX Therapeutics CTMX Stock Holding History

Perceptive Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.1M Buy
10,439,185
+340,361
+3% +$1.3M 0.59% 38
2026
Q1 		$47.5M Buy
10,098,824
+418,639
+4% +$2.12M 0.93% 27
2025
Q4 		$41.2M Hold
9,680,185
– – 0.74% 40
2025
Q3 		$30.9M Buy
9,680,185
+2,686,539
+38% +$6.05M 0.89% 34
2025
Q2 		$15.9M Buy
+6,993,646
New +$11.3M 0.59% 41
2021
Q3 		– Sell
-1,640,957
Closed -$10.4M – 145
2021
Q2 		$10.4M Sell
1,640,957
-513,017
-24% -$3.99M 0.13% 108
2021
Q1 		$16.6M Sell
2,153,974
-423,069
-16% -$3.35M 0.21% 84
2020
Q4 		$16.9M Hold
2,577,043
– – 0.18% 94
2020
Q3 		$17.1M Hold
2,577,043
– – 0.25% 72
2020
Q2 		$21.5M Sell
2,577,043
-676,880
-21% -$6.29M 0.35% 57
2020
Q1 		$25M Hold
3,253,923
– – 0.65% 39
2019
Q4 		$27M Hold
3,253,923
– – 0.54% 43
2019
Q3 		$24M Buy
3,253,923
+100,000
+3% +$986K 0.65% 36
2019
Q2 		$35.4M Sell
3,153,923
-20,000
-0.6% -$210K 0.81% 32
2019
Q1 		$34.1M Buy
3,173,923
+262,208
+9% +$3.88M 0.96% 30
2018
Q4 		$43.6M Buy
2,911,715
+250,000
+9% +$3.71M 1.66% 17
2018
Q3 		$49.2M Buy
2,661,715
+740,000
+39% +$16.9M 1.32% 24
2018
Q2 		$43.9M Sell
1,921,715
-287,097
-13% -$7.33M 1.15% 28
2018
Q1 		$62.8M Sell
2,208,812
-281,569
-11% -$8.04M 1.76% 16
2017
Q4 		$52.6M Buy
2,490,381
+1,100,000
+79% +$22.8M 1.74% 14
2017
Q3 		$25.3M Hold
1,390,381
– – 0.97% 23
2017
Q2 		$21.6M Sell
1,390,381
-140,278
-9% -$2.11M 1.08% 28
2017
Q1 		$26.4M Buy
1,530,659
+606,896
+66% +$7.99M 1.51% 20
2016
Q4 		$10.2M Buy
+923,763
New +$11.2M 0.72% 34
2016
Q3 		– Sell
-742,021
Closed -$7.58M – 200
2016
Q2 		$7.58M Hold
742,021
– – 0.53% 45
2016
Q1 		$9.57M Buy
742,021
+99,974
+16% +$1.39M 0.84% 27
2015
Q4 		$13.4M Buy
+642,047
New +$10.2M 0.99% 27

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Perceptive Advisors's CTMX Position: Q2 2026 in Review

Perceptive Advisors increased its CytomX Therapeutics (CTMX) stake by 3.4% in Q2 2026, buying an estimated $1.3M and bringing the position to 10,439,185 shares worth $39.1M. The position accounts for 0.59% of the portfolio, ranked #38.

Perceptive Advisors first reported a position in CTMX in Q4 2015 and has held it in 27 quarters since. The position peaked at $62.8M in Q1 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Perceptive Advisors held 10,439,185 shares of CytomX Therapeutics worth $39.1M as of Q2 2026.
  • Perceptive Advisors bought 340,361 CytomX Therapeutics shares in Q2 2026, an estimated $1.3M.
  • CytomX Therapeutics made up 0.59% of Perceptive Advisors's portfolio in Q2 2026, its #38 holding.
  • Perceptive Advisors first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 27 quarters since.
  • Perceptive Advisors's CytomX Therapeutics position peaked at $62.8M in Q1 2018.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.